We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Champions Oncology (CSBR - Free Report) closed at $13.43 in the latest trading session, marking a +1.13% move from the prior day. This move outpaced the S&P 500's daily gain of 0.56%. Meanwhile, the Dow gained 0.76%, and the Nasdaq, a tech-heavy index, lost 0.38%.
Prior to today's trading, shares of the company had lost 13.03% over the past month. This has lagged the Medical sector's loss of 6.31% and the S&P 500's loss of 6.76% in that time.
CSBR will be looking to display strength as it nears its next earnings release, which is expected to be December 6, 2018. Meanwhile, our latest consensus estimate is calling for revenue of $6.35 million, up 22.12% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.17 per share and revenue of $25.31 million, which would represent changes of +440% and +25.06%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CSBR. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CSBR is currently sporting a Zacks Rank of #1 (Strong Buy).
Investors should also note CSBR's current valuation metrics, including its Forward P/E ratio of 78.12. This valuation marks a premium compared to its industry's average Forward P/E of 17.54.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know
Champions Oncology (CSBR - Free Report) closed at $13.43 in the latest trading session, marking a +1.13% move from the prior day. This move outpaced the S&P 500's daily gain of 0.56%. Meanwhile, the Dow gained 0.76%, and the Nasdaq, a tech-heavy index, lost 0.38%.
Prior to today's trading, shares of the company had lost 13.03% over the past month. This has lagged the Medical sector's loss of 6.31% and the S&P 500's loss of 6.76% in that time.
CSBR will be looking to display strength as it nears its next earnings release, which is expected to be December 6, 2018. Meanwhile, our latest consensus estimate is calling for revenue of $6.35 million, up 22.12% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.17 per share and revenue of $25.31 million, which would represent changes of +440% and +25.06%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CSBR. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CSBR is currently sporting a Zacks Rank of #1 (Strong Buy).
Investors should also note CSBR's current valuation metrics, including its Forward P/E ratio of 78.12. This valuation marks a premium compared to its industry's average Forward P/E of 17.54.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.